These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26763585)

  • 21. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages.
    Rossi ME; Ruottinen H; Saunamäki T; Elovaara I; Dastidar P
    Acad Radiol; 2014 Jan; 21(1):64-71. PubMed ID: 24331266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Machine learning on brain MRI data for differential diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.
    Salvatore C; Cerasa A; Castiglioni I; Gallivanone F; Augimeri A; Lopez M; Arabia G; Morelli M; Gilardi MC; Quattrone A
    J Neurosci Methods; 2014 Jan; 222():230-7. PubMed ID: 24286700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.
    Ravina B; Tanner C; Dieuliis D; Eberly S; Flagg E; Galpern WR; Fahn S; Goetz CG; Grate S; Kurlan R; Lang AE; Marek K; Kieburtz K; Oakes D; Elliott R; Shoulson I;
    Mov Disord; 2009 Oct; 24(14):2081-90. PubMed ID: 19691116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The search for biomarkers in Parkinson's disease: a critical review.
    Antoniades CA; Barker RA
    Expert Rev Neurother; 2008 Dec; 8(12):1841-52. PubMed ID: 19086880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers of cognitive decline in Parkinson's disease.
    Lin CH; Wu RM
    Parkinsonism Relat Disord; 2015 May; 21(5):431-43. PubMed ID: 25737398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of Metabolomics-Based Biomarker Research for Parkinson's Disease.
    Li X; Fan X; Yang H; Liu Y
    Mol Neurobiol; 2022 Feb; 59(2):1041-1057. PubMed ID: 34826053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
    Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers for Parkinson's disease.
    Sherer TB
    Sci Transl Med; 2011 Apr; 3(79):79ps14. PubMed ID: 21508309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amplitude of low-frequency oscillations in Parkinson's disease: a 2-year longitudinal resting-state functional magnetic resonance imaging study.
    Hu XF; Zhang JQ; Jiang XM; Zhou CY; Wei LQ; Yin XT; Li J; Zhang YL; Wang J
    Chin Med J (Engl); 2015 Mar; 128(5):593-601. PubMed ID: 25698189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Concept of Prodromal Parkinson's Disease.
    Mahlknecht P; Seppi K; Poewe W
    J Parkinsons Dis; 2015; 5(4):681-97. PubMed ID: 26485429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers in Parkinson's disease (recent update).
    Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
    Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-invasive MR imaging of neurodegeneration in a rodent model of Parkinson's disease.
    Vernon AC; Modo M
    Methods Mol Biol; 2011; 711():487-510. PubMed ID: 21279619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiating progressive supranuclear palsy from Parkinson's disease by MRI-based dynamic cerebrospinal fluid flow.
    Fukui Y; Hishikawa N; Sato K; Yunoki T; Kono S; Matsuzono K; Nakano Y; Ohta Y; Yamashita T; Deguchi K; Abe K
    J Neurol Sci; 2015 Oct; 357(1-2):178-82. PubMed ID: 26227830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers of Parkinson's Disease: An Introduction.
    Titova N; Qamar MA; Chaudhuri KR
    Int Rev Neurobiol; 2017; 132():183-196. PubMed ID: 28554407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New markers in Parkinson's disease.
    Bougea A
    Adv Clin Chem; 2020; 96():137-178. PubMed ID: 32362317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging neurodegeneration in Parkinson's disease.
    Pavese N; Brooks DJ
    Biochim Biophys Acta; 2009 Jul; 1792(7):722-9. PubMed ID: 18992326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroimaging in Parkinson's disease: from pathology to diagnosis.
    Stoessl AJ
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S55-9. PubMed ID: 22166455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.
    Teixeira Dos Santos MC; Bell R; da Costa AN
    Bioanalysis; 2016 Dec; 8(23):2497-2518. PubMed ID: 27855513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers in Randomized Clinical Trials: Magnetic Resonance Imaging.
    Whitwell JL
    Front Neurol Neurosci; 2016; 39():101-8. PubMed ID: 27463684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.